Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists

Document Type

Journal Article

Publication Date

11-1-2024

Journal

Advances in kidney disease and health

Volume

31

Issue

6

DOI

10.1053/j.akdh.2024.08.003

Keywords

Chronic kidney disease; Consensus; Hyperkalemia; Potassium binder; Sodium zirconium cyclosilicate

Abstract

Two potassium (K) binders-patiromer sorbitex calcium and sodium zirconium cyclosilicate-are recommended by international guidelines for the management of hyperkalemia. There is, however, no universally accepted best practice for how to appropriately utilize K binders in the long-term clinical management of CKD. A panel of eight US-based nephrologists convened in October 2022 to develop a consensus statement regarding utilizing K binders in clinical practice to help manage patients with nonemergent, persistent/recurrent hyperkalemia in CKD. Consensus was reached on the following topics: (1) identifying risk factors for hyperkalemia; (2) serum K monitoring before and during K binder use; (3) utilizing K binders in patients receiving renin-angiotensin-aldosterone system inhibitors and dialysis; and (4) when to initiate K binders and their duration of use. These consensus statements for the use of K binders may assist the nephrology community in optimizing management of hyperkalemia in patients across the spectrum of CKD.

Department

Medicine

Link to Full Text

Share

COinS